KLK3 and Familial prostate cancer: This study aims to assess adherence to luteinising hormone-releasing hormone (LHRH) agonist treatment for prostate cancer (PC) in England, considering formulation-related differences, their impact on overall survival, and the association with changes in prostate-specific antigen (PSA) levels over time.